Sonrotoclax Clinical Trials
14 recruitingDrug
Phase 29Phase 34Phase 14
Showing 1–14 of 14 trials
Recruiting
Phase 3
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Chronic Lymphocytic LeukemiaSmall Lymphocytic Leukemia
Alliance for Clinical Trials in Oncology466 enrolled141 locationsNCT07321652
Recruiting
Phase 1Phase 2
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Chronic Lymphocytic LeukemiaMantle Cell LymphomaCLL+1 more
BeOne Medicines258 enrolled17 locationsNCT06697184
Recruiting
Phase 3
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines630 enrolled173 locationsNCT06943872
Recruiting
Phase 2
Study of SA+X in the Treatment of Newly Diagnosed AML
Acute Myeloid Leukemia
Ruijin Hospital205 enrolled1 locationNCT07548710
Recruiting
Phase 3
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Mantle Cell LymphomaB-cell Lymphoma
BeOne Medicines300 enrolled152 locationsNCT06742996
Recruiting
Phase 1Phase 2
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Refractory CancerB-cell LymphomaB-cell Malignancy+1 more
BeOne Medicines80 enrolled50 locationsNCT06634589
Recruiting
Phase 3
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
BeOne Medicines500 enrolled66 locationsNCT07277231
Recruiting
Phase 2
Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma (SLL)
Massachusetts General Hospital40 enrolled2 locationsNCT06849713
Recruiting
Phase 2
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
Mantle Cell Lymphoma
Canadian Cancer Trials Group40 enrolled2 locationsNCT07341191
Recruiting
Phase 1Phase 2
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
BeOne Medicines246 enrolled84 locationsNCT04973605
Recruiting
Phase 2
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Chronic Lymphocytic LeukemiaMantle Cell LymphomaRecurrent Chronic Lymphocytic Leukemia+6 more
Fred Hutchinson Cancer Center30 enrolled1 locationNCT06839053
Recruiting
Phase 1
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Diffuse Large B-Cell Lymphoma+16 more
City of Hope Medical Center37 enrolled1 locationNCT06859008
Recruiting
Phase 2
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
LymphomaMantle Cell Lymphoma
Christine Ryan60 enrolled7 locationsNCT06854003
Recruiting
Phase 2
Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment with or Without Sonrotoclax for Patients with Richter Transformation
Richter Transformation
German CLL Study Group83 enrolled11 locationsNCT04271956